Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165425 · ClinicalTrials.gov registry record · NA
Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation
A NA study of Hodgkin's Disease, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 210
- Enrollment target
- 2
- Study locations
NCT00165425 is a NA study of Hodgkin's Disease that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 210 participants, roughly in line with the 227-participant average among 20 other Hodgkin's Disease trials with a reported enrollment target. The trial reports 2 study locations across 1 state.
The verdict
NCT00165425, a NA study of Hodgkin's Disease, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 210 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to determine if it is possible to put into practice a cardiac screening program for survivors of Hodgkin's disease. In this study, we would also like to screen for cardiac risk factors that can be modified either through life-style changes or medications, to uncover significant abnormal heart findings in which treatments may be needed, and to see if there is a link between cardiac health and quality of life.
Conditions Studied
Interventions
- PROCEDURE Echo/Stress Echo
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2004-02 |
| Est. Completion | 2028-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165425
The ClinicalTrials.gov registry entry for NCT00165425 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 227-participant average among 20 other Hodgkin's Disease trials with a reported enrollment target. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin's Disease appearing as the primary indexed condition, and to 1 intervention - of which Echo/Stress Echo is the first listed.
NCT00165425 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00165425 about?
NCT00165425 is a clinical study titled "Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation". The main purpose of this study is to determine if it is possible to put into practice a cardiac screening program for survivors of Hodgkin's disease. In this study, we would also like to screen for cardiac risk factors that can be modified either through life-style changes or medications, to uncover...
What is the current status of trial NCT00165425?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 210 participants. The study started on 2004-02. Estimated completion is 2028-12.
What conditions does trial NCT00165425 study?
This clinical trial studies the following conditions: Hodgkin's Disease.
What interventions are being tested in trial NCT00165425?
The interventions under investigation include: Echo/Stress Echo (PROCEDURE).
Who is sponsoring clinical trial NCT00165425?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00165425 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
COMPLETED · NA
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
RECRUITING
-
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
RECRUITING
-
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
RECRUITING
-
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.